当前位置: 首页 >> 检索结果
241. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
作者: Fernando J Martinez.;Klaus F Rabe.;Gary T Ferguson.;Leonardo M Fabbri.;Stephen Rennard.;Gregory J Feldman.;Sanjay Sethi.;Selwyn Spangenthal.;Gregory M Gottschlich.;Roberto Rodriguez-Roisin.;Samir Arora.;Thomas M Siler.;Shahid Siddiqui.;Patrick Darken.;Tracy Fischer.;Andrea Maes.;Michael Golden.;Chad Orevillo.;Colin Reisner.
来源: Chest. 2017年151卷2期340-357页
Long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combinations are a treatment option for patients with COPD who continue to have symptoms despite treatment with a LAMA or a LABA alone. The Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate-to-Very Severe COPD (PINNACLE-1) (NCT01854645) and the Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate-to-Very Severe COPD (PINNACLE-2) (NCT01854658) trials investigated the efficacy and safety of a novel glycopyrrolate [GP]/formoterol [FF] 18/9.6-μg (GFF) metered dose inhaler (MDI) formulated using the Co-Suspension Delivery Technology in patients with moderate-to-very severe COPD.
242. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial.
作者: Marin H Kollef.;Jean-Damien Ricard.;Damien Roux.;Bruno Francois.;Eleni Ischaki.;Zsolt Rozgonyi.;Thierry Boulain.;Zsolt Ivanyi.;Gál János.;Denis Garot.;Firas Koura.;Epaminondas Zakynthinos.;George Dimopoulos.;Antonio Torres.;Wayne Danker.;A Bruce Montgomery.
来源: Chest. 2017年151卷6期1239-1246页
Clinical failures in ventilator-associated pneumonia (VAP) caused by gram-negative bacteria are common and associated with substantial morbidity, mortality, and resource utilization.
243. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
作者: Marilyn K Glassberg.;Julia Minkiewicz.;Rebecca L Toonkel.;Emmanuelle S Simonet.;Gustavo A Rubio.;Darcy DiFede.;Shirin Shafazand.;Aisha Khan.;Marietsy V Pujol.;Vincent F LaRussa.;Lisa H Lancaster.;Glenn D Rosen.;Joel Fishman.;Yolanda N Mageto.;Adam Mendizabal.;Joshua M Hare.
来源: Chest. 2017年151卷5期971-981页
Despite Food and Drug Administration approval of 2 new drugs for idiopathic pulmonary fibrosis (IPF), curative therapies remain elusive and mortality remains high. Preclinical and clinical data support the safety of human mesenchymal stem cells as a potential novel therapy for this fatal condition. The Allogeneic Human Cells (hMSC) in patients with Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER) trial was the first study designed to evaluate the safety of a single infusion of bone marrow-derived mesenchymal stem cells in patients with idiopathic pulmonary fibrosis.
244. Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.
作者: Lucy Yang.;Joseph Cheriyan.;David D Gutterman.;Ruth J Mayer.;Zsuzsanna Ament.;Jules L Griffin.;Aili L Lazaar.;David E Newby.;Ruth Tal-Singer.;Ian B Wilkinson.
来源: Chest. 2017年151卷3期555-563页
Smoking and COPD are risk factors for cardiovascular disease, and the pathogenesis may involve endothelial dysfunction. We tested the hypothesis that endothelium-derived epoxyeicosatrienoic acid (EET)-mediated endothelial function is impaired in patients with COPD and that a novel soluble epoxide hydrolase inhibitor, GSK2256294, attenuates EET-mediated endothelial dysfunction in human resistance vessels both in vitro and in vivo.
245. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.
作者: Ivan F N Hung.;Kelvin K W To.;Jasper F W Chan.;Vincent C C Cheng.;Kevin S H Liu.;Anthony Tam.;Tuen-Ching Chan.;Anna Jinxia Zhang.;Patrick Li.;Tin-Lun Wong.;Ricky Zhang.;Michael K S Cheung.;William Leung.;Johnson Y N Lau.;Manson Fok.;Honglin Chen.;Kwok-Hung Chan.;Kwok-Yung Yuen.
来源: Chest. 2017年151卷5期1069-1080页
Influenza causes excessive hospitalizations and deaths. The study assessed the efficacy and safety of a clarithromycin-naproxen-oseltamivir combination for treatment of serious influenza.
246. Stylet Use Does Not Improve Diagnostic Outcomes in Endobronchial Ultrasonographic Transbronchial Needle Aspiration: A Randomized Clinical Trial.
作者: Eric L Scholten.;Roy Semaan.;Peter Illei.;Christopher Mallow.;Sixto Arias.;David Feller-Kopman.;Karen Oakjones-Burgess.;Bernice Frimpong.;Ricardo O Amador.;Hans Lee.;Lonny Yarmus.
来源: Chest. 2017年151卷3期636-642页
Endobronchial ultrasonographically guided transbronchial needle aspiration (EBUS-TBNA) of thoracic structures is a commonly performed tissue sampling technique. The use of an inner-stylet in the EBUS needle has never been rigorously evaluated and may be unnecessary.
247. Association Between Insomnia and Asthma Burden in the Severe Asthma Research Program (SARP) III.
作者: Faith S Luyster.;Patrick J Strollo.;Fernando Holguin.;Mario Castro.;Eleanor M Dunican.;John Fahy.;Benjamin Gaston.;Elliot Israel.;Nizar N Jarjour.;David T Mauger.;Wendy C Moore.;Sally E Wenzel.
来源: Chest. 2016年150卷6期1242-1250页
Sleep difficulties are commonly reported by patients with asthma; however, the prevalence of insomnia and its association with disease burden and well-being is unknown. We aimed to determine the prevalence of insomnia, defined as combined sleep-specific complaints with associated daytime symptoms, among a large sample of adults with asthma, and to compare well-being, asthma control, and asthma-related health care utilization in individuals with asthma and insomnia and those without insomnia.
248. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
作者: Sanjay Mehta.;Bhagavatula Kutumba Srinivasa Sastry.;Rogério Souza.;Adam Torbicki.;Hossein-Ardeschir Ghofrani.;Richard N Channick.;Marion Delcroix.;Tomás Pulido.;Gérald Simonneau.;John Wlodarczyk.;Lewis J Rubin.;Pavel Jansa.;Elke Hunsche.;Nazzareno Galiè.;Loïc Perchenet.;Olivier Sitbon.
来源: Chest. 2017年151卷1期106-118页
Pulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The association between baseline HRQoL and long-term outcomes was also investigated.
249. Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival.
作者: Ying Zhou.;Elyse E Lower.;Hui-Ping Li.;Alexandru Costea.;Mehran Attari.;Robert P Baughman.
来源: Chest. 2017年151卷1期139-148页
To assess the clinical characteristics, diagnosis, and outcome of cardiac sarcoidosis in a single institution sarcoidosis clinic.
250. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial.
作者: Robert C Bourge.;Aaron B Waxman.;Mardi Gomberg-Maitland.;Shelley M Shapiro.;James H Tarver.;Dianne L Zwicke.;Jeremy P Feldman.;Murali M Chakinala.;Robert P Frantz.;Fernando Torres.;Jeffrey Cerkvenik.;Marty Morris.;Melissa Thalin.;Leigh Peterson.;Lewis J Rubin.
来源: Chest. 2016年150卷1期27-34页
The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often limited by patient/physician dissatisfaction with the delivery methods. Complications associated with external pump-delivered continuous therapy include IV catheter-related bloodstream infections and subcutaneous infusion site pain. We therefore investigated a fully implantable intravascular delivery system for treprostinil infusion.
251. The COPD Assessment Test: Can It Discriminate Across COPD Subpopulations?
作者: Nisha Gupta.;Lancelot Pinto.;Andrea Benedetti.;Pei Zhi Li.;Wan C Tan.;Shawn D Aaron.;Kenneth R Chapman.;J Mark FitzGerald.;Paul Hernandez.;Darcy D Marciniuk.;François Maltais.;Denis E O'Donnell.;Don Sin.;Brandie L Walker.;Jean Bourbeau.; .
来源: Chest. 2016年150卷5期1069-1079页
The COPD Assessment Test (CAT) is a valid disease-specific questionnaire measuring health status. However, knowledge concerning its use regarding patient and disease characteristics remains limited. Our main objective was to assess the degree to which the CAT score varies and can discriminate between specific patient population groups.
252. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
作者: Philip S Wells.;Martin H Prins.;Bennett Levitan.;Jan Beyer-Westendorf.;Timothy A Brighton.;Henri Bounameaux.;Alexander T Cohen.;Bruce L Davidson.;Paolo Prandoni.;Gary E Raskob.;Zhong Yuan.;Eva G Katz.;Martin Gebel.;Anthonie W A Lensing.
来源: Chest. 2016年150卷5期1059-1068页
Short-term anticoagulant treatment for acute DVT or pulmonary embolism (PE) effectively reduces the risk of recurrent disease during the first 6 to 12 months of therapy. Continued anticoagulation often is not instituted because of the perception among physicians that the risk of major bleeding will outweigh the risk of new venous thrombotic episodes.
253. Single-Breath Washout Tests to Assess Small Airway Disease in COPD.
作者: Lucas Boeck.;Anna Gensmer.;Sylvia Nyilas.;Bram Stieltjes.;Thomas J Re.;Michael Tamm.;Philipp Latzin.;Daiana Stolz.
来源: Chest. 2016年150卷5期1091-1100页
Current functional assessments do not allow a reliable assessment of small airways, which are a major site of disease in COPD. Single-breath washout (SBW) tests are feasible and reproducible methods for evaluating small airway disease. Their relevance in COPD remains unknown.
254. Acute Effects of Nasal CPAP in Patients With Hypertrophic Cardiomyopathy.
作者: Flávia B Nerbass.;Vera M C Salemi.;Rodrigo P Pedrosa.;Natanael de P Portilho.;Julio C A Ferreira-Filho.;Henrique T Moriya.;Murillo O Antunes.;Edmundo Arteaga-Fernández.;Luciano F Drager.;Geraldo Lorenzi-Filho.
来源: Chest. 2016年150卷5期1050-1058页
Hypertrophic cardiomyopathy (HCM) is a common genetic disease that may cause left ventricular outflow tract (LVOT) obstruction, heart failure, and sudden death. Recent studies have shown a high prevalence of OSA among patients with HCM. Because the hemodynamics in patients with LVOT obstruction are unstable and depend on the loading conditions of the heart, we evaluated the acute effects of CPAP on hemodynamics and cardiac performance in patients with HCM.
255. Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study.
作者: Alain Tremblay.;Niloofar Taghizadeh.;Annette M McWilliams.;Paul MacEachern.;David R Stather.;Kam Soghrati.;Serge Puksa.;John R Goffin.;Kazuhiro Yasufuku.;Kayvan Amjadi.;Garth Nicholas.;Simon Martel.;Francis Laberge.;Michael Johnston.;Frances A Shepherd.;Diana N Ionescu.;Stefan Urbanski.;David Hwang.;Jean-Claude Cutz.;Harmanjatinder S Sekhon.;Christian Couture.;Zhaolin Xu.;Tom G Sutedja.;Sukhinder Atkar-Khattra.;Martin C Tammemagi.;Ming-Sound Tsao.;Stephen C Lam.; .
来源: Chest. 2016年150卷5期1015-1022页
Lung cancer screening with low-dose CT (LDCT) scan has been demonstrated to reduce lung cancer mortality. Preliminary reports suggested that up to 20% of lung cancers may be CT scan occult but detectable by autofluorescence bronchoscopy (AFB). We evaluated the prevalence of CT scan occult, invasive, and high-grade preinvasive lesions in high-risk participants undergoing screening for lung cancer.
256. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.
作者: Borja G Cosío.;Hanaa Shafiek.;Amanda Iglesias.;Aina Yanez.;Rocío Córdova.;Alexandre Palou.;Robert Rodriguez-Roisin.;Germán Peces-Barba.;Sergi Pascual.;Joaquim Gea.;Oriol Sibila.;Peter J Barnes.;Alvar Agusti.
来源: Chest. 2016年150卷1期123-30页
COPD is characterized by chronic inflammation. In vitro and ex vivo observations suggest that this inflammatory response is partially resistant to the effect of corticosteroids and that low-dose theophylline can restore this response via enhancement of histone deacetylase (HDAC) activity. Whether this occurs in vivo and what its potential clinical consequences are is unclear.
257. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
作者: Leif Bjermer.;Catherine Lemiere.;Jorge Maspero.;Sivan Weiss.;James Zangrilli.;Matthew Germinaro.
来源: Chest. 2016年150卷4期789-798页
This phase 3 study further characterizes the efficacy and safety of reslizumab (a humanized anti-IL-5 monoclonal antibody) in patients aged 12 to 75 years with asthma inadequately controlled by at least a medium-dose inhaled corticosteroid and with a blood eosinophil count ≥ 400 cells/μL.
258. A Prospective, Randomized, Double-Blind Trial Comparing the Diagnostic Yield of 21- and 22-Gauge Aspiration Needles for Performing Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Sarcoidosis.
作者: Valliappan Muthu.;Nalini Gupta.;Sahajal Dhooria.;Inderpaul Singh Sehgal.;Amanjit Bal.;Ashutosh N Aggarwal.;Digambar Behera.;Ritesh Agarwal.
来源: Chest. 2016年149卷4期1111-3页 259. Oxygen With Cold Bubble Humidification Is No Better Than Dry Oxygen in Preventing Mucus Dehydration, Decreased Mucociliary Clearance, and Decline in Pulmonary Function.
作者: Michelle Lisidati Franchini.;Rodrigo Athanazio.;Luis Fernando Amato-Lourenço.;Waldir Carreirão-Neto.;Paulo Hilario Nascimento Saldiva.;Geraldo Lorenzi-Filho.;Bruce K Rubin.;Naomi Kondo Nakagawa.
来源: Chest. 2016年150卷2期407-14页
Little is known about the effects of long-term nasal low-flow oxygen (NLFO) on mucus and symptoms and how this variable is affected by dry or cold humidified gas. The aim of this study was to investigate the effects of dry-NLFO and cold bubble humidified-NLFO on nasal mucociliary clearance (MCC), mucus properties, inflammation, and symptoms in subjects with chronic hypoxemia requiring long-term domiciliary oxygen therapy.
260. B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS.
作者: Matthew W Semler.;Annis M Marney.;Todd W Rice.;Hui Nian.;Chang Yu.;Arthur P Wheeler.;Nancy J Brown.; .
来源: Chest. 2016年150卷1期102-11页
Conservative fluid management increases ventilator-free days without influencing overall mortality in acute respiratory distress syndrome. Plasma concentrations of B-type natriuretic peptide (a marker of ventricular filling) or aldosterone (a marker of effective circulating volume) may identify patients for whom fluid management impacts survival.
|